Last reviewed · How we verify
FluMist/B/Victoria
FluMist is a live attenuated influenza vaccine that stimulates immune response by delivering weakened influenza virus strains intranasally.
FluMist is a live attenuated influenza vaccine that stimulates immune response by delivering weakened influenza virus strains intranasally. Used for Influenza prevention in children and adults (seasonal influenza prophylaxis).
At a glance
| Generic name | FluMist/B/Victoria |
|---|---|
| Also known as | FluMist |
| Sponsor | MedImmune LLC |
| Drug class | Live attenuated influenza vaccine (LAIV) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
FluMist contains live, temperature-sensitive attenuated influenza virus strains that replicate in the cooler upper respiratory tract but cannot replicate in the warmer lower respiratory tract, thereby inducing both mucosal and systemic immunity without causing disease. The vaccine is administered as a nasal spray and triggers innate and adaptive immune responses against the included influenza virus strains. The B/Victoria strain component targets protection against influenza B virus of the Victoria lineage.
Approved indications
- Influenza prevention in children and adults (seasonal influenza prophylaxis)
Common side effects
- Nasal congestion
- Runny nose
- Sore throat
- Cough
- Fever
- Myalgia
Key clinical trials
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age (PHASE3)
- Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults (PHASE1)
- Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults (PHASE1)
- Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children . (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine (PHASE3)
- The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older (PHASE3)
- Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine (PHASE2, PHASE3)
- Safety and Immunogenicity of the Butantan Quadrivalent Influenza Vaccine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FluMist/B/Victoria CI brief — competitive landscape report
- FluMist/B/Victoria updates RSS · CI watch RSS
- MedImmune LLC portfolio CI